Search results for PX-TA1009

Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade, ProteoGenix, PX-TA1009

Description of Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade General information about Infliximab Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.